Dr. Éric Vigneault is a radiation oncologist-clinician in the Department of Radiation Oncology at CHUQ, and a researcher in the oncology axis of the CHU Research Centre of Laval University-Quebec, affiliated with the Centre for Cancer Research at Laval University.

He is also Associate Clinical Professor in the Department of Medicine of the Faculty of Medicine at Laval University. Dr. Vigneault has been actively involved in the development of the first Iodine-125 prostate brachytherapy program in Canada, and is the pioneer of high dose-rate, non-permanent brachytherapy in Canada. He is the principal investigator of randomized phase II CCTG studies, comparing HDR brachytherapy with conventional radiotherapy in the treatment of intermediate-risk prostatic cancers (PR15), and comparing HDR brachytherapy with LDR monotherapy (PR19).

Dr. Vigneault is deeply involved at the national level, including as the former President of the Canadian Association of Radiation Oncologists, as a member of the Steering Committee of the Canadian Urologic Oncology Group (CUOG), as well as internationally as the Associate Editor of the Brachytherapy journal.

Since 2015, he holds the Research Chair in Image-guided Brachytherapy, whose mission is to integrate technological advances in the field of imaging, computer science, dosimetry optimization, radioactive source implantation systems, as well as clinical expertise to improve brachytherapy treatments for solid tumors, thereby promoting a better therapeutic ratio – i.e., an increase in tumor control and a decrease in toxicity. This research Chair is part of Laval University’s Program for the Advancement of Innovation, Research and Teaching, which aims to create a research environment that stimulates innovation, inventiveness and creativity among research professors.

The objectives of the Chair are:

  1. Improve the integration of real-time imaging, implantation and dosimetry systems to improve the quality and accuracy of radioactive material implantation in cancers.
  2. Develop protocols for treating tumor sites by brachytherapy.
  3. Promote clinical research to evaluate and compare tumor controls, toxicities, and quality of life assessment with conventional treatment, including dissemination of results and knowledge transfer;
  4. Promote the education and training of graduate students and fellows in the field of brachytherapy;
  5. Develop clinical databases of tissue banks collected to support translational research.
L'Hôtel-Dieu de Québec
Hôtel-Dieu de Québec
11, Côte du Palais, Bureau 3336
Québec, Québec
Canada G1R 2J6
+1 418-691-5264
eric.vigneault@chudequebe... eric.vigneault@crchudeque...

Latest news

85 entries « ‹ 1 of 9 › »

Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY

Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377

Journal Article

Int J Radiat Oncol Biol Phys, 120 (5), 2024.

| Links:

Carignan D, Morales B, Després P, Foster W, Martin AG, Vigneault E

Differential outcomes of re-stratified high-risk prostate cancer patients treated with external beam radiation therapy plus high-dose-rate brachytherapy boost

Journal Article

J Contemp Brachytherapy, 16 (2), 2024.

Abstract | Links:

Mansour IR, Miksys N, Beaulieu L, Vigneault É, Thomson RM

Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy

Journal Article

Brachytherapy, 2024.

Abstract | Links:

Nabid A, Carrier N, Vigneault E, Martin AG, Bahary JP, Van Nguyen T, Vavassis P, Vass S, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Duclos M, Wilke D, Souhami L

Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials

Journal Article

Radiother Oncol, 195 , 2024.

Abstract | Links:

Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CAF, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial

Journal Article

JAMA Oncol, 10 (5), 2024.

Abstract | Links:

Lavallee MC, Cantin A, Aubin S, Lefebvre M, Marrier AS, Bouchard I, Fiset C, Villeneuve-Gauthier A, Foster W, Martin AG, Carignan D, Beaulieu L, Vigneault E

US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment

Journal Article

Brachytherapy, 23 (1), 2024.

Abstract | Links:

Beaudry MM, Carignan D, Foster W, Lavallee MC, Aubin S, Lacroix F, Poulin E, Lachance B, Després P, Beaulieu L, Vigneault E, Martin AG

Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial

Journal Article

Clin Transl Radiat Oncol, 40 , 2023.

Abstract | Links:

Kamrava M, Leung E, Bachand F, Beriwal S, Chargari C, D'Souza D, Erickson B, Fokdal L, Han K, Harkenrider M, Lin L, Mahantshetty U, Nesvacil N, Ravi A, Schmid M, Vigneault E, Westerveld H, Yashar C, Nout R

GEC-ESTRO (ACROP)-ABS-CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina

Journal Article

Int J Radiat Oncol Biol Phys, 115 (3), 2023.

Abstract | Links:

Corkum MT, Buyyounouski MK, Chang AJ, Chung HT, Chung P, Cox BW, Crook JM, Davis BJ, Frank SJ, Henriquez I, Horwitz EM, Hoskin P, Hsu IC, Keyes M, King MT, Kollmeier MA, Krauss DJ, Kukielka AM, Morton G, Orio PF, Pieters BR, Potters L, Rossi PJ, Showalter TN, Solanki AA, Song D, Vanneste B, Vigneault E, Wojcieszek PA, Zelefsky MJ, Kamrava M

Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study

Journal Article

Radiother Oncol, 184 , 2023.

Abstract | Links:

Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID,

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Journal Article

Lancet Oncol, 24 (4), 2023.

Abstract | Links:

85 entries « ‹ 1 of 9 › »
Signaler des ajouts ou des modifications

Active projects

  • 2SHARP:Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer. , from 2024-06-19 to 2025-03-31
  • Chaire de recherche sur la curiethérapie guidée par imagerie (phase 2), from 2022-11-01 to 2029-10-31
  • Parallel Phase III Randomized Trials of Genomic-risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-intensification and Intensification Clinical Trial Evaluation (GUIDANCE), from 2023-07-24 to 2025-02-28
  • The association of circulating tumor DNA with tumor control and toxicity in prostate cancer patients treated with EBRT and HDR brachytherapy boost , from 2024-02-06 to 2025-02-05
  • The impact of Monte Carlo dose calculations on prostate and breast low-dose rate brachytherapy dose-outcome relationships and radiobiological modeling, from 2020-10-01 to 2025-09-30
  • The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer, from 2024-02-22 to 2025-02-21

Recently finished projects

  • Chaire de recherche sur la curiethérapie guidée par imagerie, from 2015-05-01 to 2023-03-31
  • Phase 2 randomized pilot study on the impacts of diet, cellular nutrition and physical activity on hormone therapy toxicity., from 2023-08-31 to 2024-08-30
Data provided by the Université Laval research projects registery